News articles about CTI BioPharma Corp. (NASDAQ:CTIC) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CTI BioPharma Corp. earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 47.8727366668964 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of research firms have commented on CTIC. Jefferies Group LLC began coverage on shares of CTI BioPharma Corp. in a research report on Tuesday, September 12th. They set a “buy” rating and a $7.50 price target on the stock. ValuEngine downgraded shares of CTI BioPharma Corp. from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 11th.
Shares of CTI BioPharma Corp. (NASDAQ CTIC) opened at $2.76 on Monday. CTI BioPharma Corp. has a 52-week low of $2.70 and a 52-week high of $6.48. The company has a current ratio of 2.19, a quick ratio of 2.17 and a debt-to-equity ratio of 0.26.
CTI BioPharma Corp. (NASDAQ:CTIC) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. CTI BioPharma Corp. had a negative net margin of 96.91% and a negative return on equity of 209.67%. The company had revenue of $1.71 million for the quarter, compared to the consensus estimate of $0.30 million. equities research analysts forecast that CTI BioPharma Corp. will post -1.2 earnings per share for the current year.
In related news, Director Richard L. Love sold 14,600 shares of the business’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $3.21, for a total value of $46,866.00. Following the sale, the director now directly owns 84,318 shares in the company, valued at approximately $270,660.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.08% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2017/11/20/cti-biopharma-corp-ctic-earning-somewhat-positive-press-coverage-report-finds.html.
About CTI BioPharma Corp.
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.